Skip to content

Efficacy and safety of entrectinib▼ in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

Entrectinib▼ is a tyrosine kinase inihbitor approved globally for the treatment of NTRK fusion-positive solid tumours, based on the results of three phase 1/2 trials (ALKA-372-001; STARTRK-1; STARTRK-2). Updated results (enrolment cut-off: 31 Jul 2019; clinical cut-off 31 Aug 2020) are presented.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically